MATTHEW MONTGOMERY: Open Payments
NPI 1942549860 · SHEFFIELD, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$855 in 36 payments from 11 companies in 2025. Trend: 2023 $792 · 2024 $978 · 2025 $855
Food & beverage: $776Education: $79
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $292 |
| GENZYME CORPORATION | 6 | $99 |
| Insmed, Inc. | 4 | $93 |
| Novo Nordisk Inc | 1 | $81 |
| SANOFI-AVENTIS U.S. LLC | 1 | $79 |
| Regeneron Healthcare Solutions, Inc. | 4 | $78 |
| GlaxoSmithKline, LLC. | 3 | $52 |
| ABBVIE INC. | 1 | $25 |
| Merck Sharp & Dohme LLC | 1 | $20 |
| 3B Medical, Inc. | 1 | $20 |
Products named: DUPIXENT, Arikayce, FARXIGA, NUCALA, TEZSPIRE, DALVANCE, ZERBAXA, LUNA.
Industry payments across AL — which companies pay providers there.
